Asia
Cambridge, Mass.-based Biogen exercised its option to acquire additional shares of South Korea’s Samsung Bioepis. Samsung Bioepis focuses on developing biosimilar drugs and is a joint venture between Samsung Biologics and Biogen formed in 2012.
At the 11th Clinical Trials in Alzheimer’s Disease Conference
An above-average rise at 4% volume CAGR is foreseen for the syringes & cannulas market over the period of forecast, 2018 to 2028, by a new Fact.MR study.
Janssen agreed to pay Yuhan $50 million in upfront money. Yuhan said that Janssen will be responsible for the development of lazertinib. Janssen will also be responsible for manufacturing and commercialization of the drug.
On a Structurally Novel Class of Sting Agonist at 33rd Sitc Annual Meeting
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.
BeiGene, Ltd. today announced the acceptance by the China National Medical Products Administration (NMPA) of a new drug application (NDA) for zanubrutinib, an investigational Bruton’s tyrosine kinase (BTK) inhibitor
Chief Medical and Development Officer Debra Barker has decided to leave Polyphor at year end for personal reasons and will support on a part time basis afterwards.
Tan will lead the positioning of Cerecin’s pipeline of highly innovative neurotherapeutics
Eisai Co., Ltd. and Meiji Seika Pharma Co., Ltd. announced that an application seeking manufacturing and marketing approval in Japan was submitted as of today by Meiji for the Parkinson’s disease treatment ME2125 (safinamide mesylate, “safinamide”).
PRESS RELEASES